Tim-Brim-Dorâ„¢ PF   (U.S.N.L.M.)
Dosing q.a.m. This is the AM arm of the "Triple/Quad, AM - PM pairing".
It is intended for use in unison with the quad "PM combination"1.
Chem Specs timolol 0.5%,  brimonidine 0.15%,   dorzolamide 2.0%,
Quantities 10ml,
Cost 150.00
Class timolol:           Non-selective beta-adrenergic receptor blocker.
brimonidine:   Relatively selective alpha-2 agonist.
dorzolamide:   Carbonic anhydrase inhibitor
Usage The preservative-free, single container preparation can reduce surface toxicity
and enhance compliance.

Bronchial asthma, a history of bronchial asthma, COPD, sinus bradycardia,
second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock.
Numerous additional cautions listed here.


neonates and infants (under the age of 2 years)
Vascular insufficiency cautions listed here.


Sulfonamide hypersensitivity.
Pediatric use Safety and effectiveness in pediatric patients have not been established.
Pregnancy Category C. Teratogenicity shown in rabbits at 37x the human dose but not at 16x.
1. The "PM combination" Tim-Brim-Dor-Latâ„¢ is similar but adds latanaprost (daily dosing).
Bottle with one way valve requires refrigeration.
Individual drugs are FDA approved but the combination is not.